What is AICAR?
AICAR (5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside), also known as Acadesine, is a nucleotide analog that acts as an activator of AMPK (AMP-activated protein kinase), the enzyme considered the cell’s “master energy sensor.”
The popular term “exercise in a syringe” that circulates in research literature is not entirely arbitrary: preclinical studies in murine models documented improvements in aerobic endurance and metabolic adaptations in sedentary animals that had never run. However, this description oversimplifies a complex mechanism and has no backing from controlled human clinical trials.
Important: AICAR is a research compound not approved for human use. It is expressly prohibited by WADA (World Anti-Doping Agency) in competitive sports. Available data comes almost exclusively from animal models. This page is for educational purposes only and does not constitute medical advice.
Mechanism of Action
After administration, AICAR is taken up by cells and converted intracellularly into ZMP (AICA ribonucleotide monophosphate), a structural analog of AMP (adenosine monophosphate).
Signaling cascade:
- ZMP accumulates intracellularly and mimics the rise in AMP that occurs during intense exercise.
- ZMP activates AMPK (AMP-dependent kinase), a heterotrimer that acts as the central regulator of cellular energy metabolism.
- Activated AMPK triggers multiple coordinated responses:
- Fatty acid oxidation: Inhibition of ACC (acetyl-CoA carboxylase) → reduction of malonyl-CoA → increased fatty acid transport into mitochondria.
- Glucose uptake: Translocation of GLUT4 to the plasma membrane → increased muscle glucose uptake.
- Mitochondrial biogenesis: Activation of PGC-1α → increased mitochondrial density.
- Metabolic gene expression: Transcriptional changes that mimic those observed after prolonged aerobic exercise.
The reference study: The paper by Narkar et al. (2008) published in Cell documented that sedentary mice treated with AICAR for 4 weeks improved their treadmill endurance by 44% compared to the control group, and showed changes in muscle fiber profile toward type I (endurance). This study is the foundation of the compound’s reputation.
Reported Research Protocol
The following table reflects escalation protocols described in animal research literature. No validated protocol exists for human use.
| Phase | Reported Dose | Duration |
|---|---|---|
| Weeks 1-2 (initiation) | 1 mg/day SC | 14 days |
| Weeks 3-4 (escalation) | 2 mg/day SC | 14 days |
| Weeks 5-8 (maintenance) | 3 mg/day SC | 28 days |
| Advanced phase (animal models) | Up to 5 mg/day SC | Variable |
Vial reconstitution (50 mg):
- Add 3.0 mL of bacteriostatic water → concentration 16.7 mg/mL.
- At this concentration: 1 unit (U-100) = 167 mcg.
- For 1 mg → 6 units (0.06 mL).
- For 3 mg → 18 units (0.18 mL).
Note on the vial: With 50 mg and doses of 1-3 mg/day, a vial lasts between 10 and 50 days of use. Plan reconstitution and storage accordingly.
Effects Reported in Research (primarily murine models)
- Improved aerobic endurance: Documented ~44% increase in running capacity in sedentary mice after 4 weeks of treatment.
- Body fat oxidation: Increased beta-oxidation and reduced fat mass in obesity models.
- Insulin sensitivity: Improved AMPK-mediated glucose uptake; potentially relevant in insulin resistance models.
- Mitochondrial biogenesis: Increased mitochondrial density and efficiency in skeletal muscle.
- Protection against diabetic neuropathy: In vitro and animal model data suggest neuroprotective effects.
- Cardioprotective effects: Documented in ischemia-reperfusion models.
Described Adverse Effects
Safety data in humans is extremely limited:
- Transient hypoglycemia: GLUT4-mediated increase in glucose uptake can reduce blood glucose. Monitor symptoms especially when fasting.
- Fatigue: Reported in some individuals; possibly related to the metabolic effect of AMPK activation.
- Insufficient human data: No long-term safety studies in humans exist. Use in human athletes is experimental and unvalidated.
- WADA ban: Use in competition constitutes a violation of anti-doping rules with severe sporting consequences.
Storage
| State | Temperature | Duration |
|---|---|---|
| Lyophilized (unreconstituted) | -20°C | Up to 24 months |
| Reconstituted | 2-8°C (refrigeration) | Up to 4 weeks |
Greater stability than protein peptides: AICAR is a nucleotide and tolerates standard storage conditions better. Avoid exposure to direct light and heat.
Legal disclaimer: This content is for educational purposes only. Not medical advice. Always consult a healthcare professional.
Reported protocol (research reference)
| Vial sizes | 50 mg |
|---|---|
| Reported dose | Animal model research literature reports ranges of 1-5 mg/day SC, with gradual escalation. Human data is extremely limited. |
| Half-life | Not well characterized in humans; active renal elimination. Metabolic effects persist beyond the compound's half-life through sustained AMPK activation. |
| FDA status | Not FDA approved |